| Page 15 | Aplastic Anemia and MDS International Foundation

Kansas City

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
Event Date: 
Sat, 10/14/2017 -
7:30am to 1:30pm
Conference Event Type: 

Haploidentical transplant in patients with myelodysplastic syndrome

Author(s): 
Marie Robin, Raphael Porcher, Fabio Ciceri, Maria Teresa van Lint, Stella Santarone, Gerhard Ehninger, Didier Blaise, Zafer Güllbas, Soledad Gonzáles Muñiz, Mauricette Michallet, Andrea Velardi, Linda Koster, Johan Maertens, Jorge Sierra
Primary Author: 
Marie Robin
Journal Title: 
Blood Advances
Original Publication Date: 
Jul 2017

The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option.

Bone Marrow Diseases: 

Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia

Author(s): 
NCI Staff
Primary Author: 
NCI Staff
Journal Title: 
NIHNCI
Original Publication Date: 
Sep 2017

On September 1, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (Mylotarg™) for some patients with acute myeloid leukemia (AML).

The approval covers the use of gemtuzumab in adults with newly diagnosed AML that expresses a protein called CD33 (CD33-positive AML). The approval also covers the treatment of patients aged 2 and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.

Bone Marrow Diseases: 

Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype

Author(s): 
Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Jeffrey Medeiros L, Wang SA
Primary Author: 
Wang W
Journal Title: 
Eur J Haematol
Original Publication Date: 
Sep 2017

OBJECTIVES:

Although commonly associated with high-grade myelodysplastic syndrome (MDS) and MDS with a complex karyotype, TP53 mutations also occur in low-grade MDS and MDS with a non-complex karyotype. In latter cases, their clinicopathological features and the characteristics of TP53 mutations remain poorly characterized.

METHODS:

176 MDS cases with TP53 mutations were stratified and characterized based on their karyotype and histologic subtype.

Bone Marrow Diseases: 

Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

Author(s): 
Mies A, Platzbecker U
Primary Author: 
Mies A
Journal Title: 
Semin Hematol
Original Publication Date: 
Sep 2017

Patients with lower-risk

Bone Marrow Diseases: 

Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

Author(s): 
Madanat Y, Sekeres MA
Primary Author: 
Madanat Y
Journal Title: 
Semin Hematol
Original Publication Date: 
Sep 2017

Bone Marrow Diseases: 

Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

Author(s): 
Zhao X, Feng X, Wu Z, Winkler T, Desmond R, Olnes M, Dumitriu B, Townsley DM, Dunbar CE, Young NS
Primary Author: 
Zhao X
Journal Title: 
Exp Hematol
Original Publication Date: 
Sep 2017

Although hematopoietic growth factors are at high levels in

Bone Marrow Diseases: 

Clinical trial reveals genetic fault that reduces the effectiveness of leukemia treatment

Author(s): 
University of Birmingham
Primary Author: 
University of Birmingham
Journal Title: 
Science Codex
Original Publication Date: 
Sep 2017

A genetic fault has been identified in people with an aggressive type of leukaemia that can significantly affect how they respond to treatment.